Pediatric Psychopharmacology: A Review of New Developments and Recent Research

Professional Psychology: Research and Practice

Volumn 33, Issue 2, 2002, Pages 135-147

  Brown, Ronald T ^a,c,d   Sammons, Morgan T ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Naval Medical Clinic   (United States)

^c Department of Pediatrics ^*  (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0042126154     PISSN: 07357028     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7028.33.2.135     Document Type: Review

References (135)

1. Abbot Pharmaceuticals. (1996). Important drug warning [Letter]. North Chicago: Author.
2. Achenbach, T. M., McConaughy, S. H., & Howell, C. T. (1987). Child/adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychological Bulletin, 101, 213-232.
3. Alderman, J., Wolkow, R., Chung, M., & Johnston, H. F. (1998). Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: Pharmacokinetics, tolerability and efficacy. Journal of American Academy of Child and Adolescent Psychiatry, 37, 386-394.
4. Allen, A. J., Leonard, H., & Swedo, S. (1995). Current knowledge of medications for the treatment of childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 976-986.
5. Aman, M. G., & Pearson, D. A. (1999). Monitoring and measuring drug effects: Part 2. Behavioral, emotional, and cognitive effects. In J. Werry & M. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 99-164). New York: Plenum.
6. Aman, M. G., & Singh, N. N. (1988). Psychopharmacotherapy of the developmental disabilities. Berlin: Springer-Verlag.
7. Aman, M. G., VanBourgodien, M. E., Wolford, P. L., & Saphire, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672-1681.
8. Ambrossini, P., Wagner, K., Biederman, J., Glick, I., Tan, C., Elia, J., et al. (1999). Multicenter open-label sertraline study in adolescent outpatients with depression. Journal of the American Academy of Child and Adolescent Psychiatry, 37S, 63S-83S.
9. American Academy of Pediatrics. (1985). Behavioral and cognitive effects of anticonvulsant therapy. Pediatrics. 76, 644-647.
10. American Academy of Pediatrics. (2000). Clinical practice guideline: Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics, 105, 109-133.
11. American Academy of Pediatrics. (2001). Clinical practice guideline: Treatment of the child with attention-deficit/hyperactivity disorder. Pediatrics, 105, 1158-1170.
12. American Psychological Association. (1996, February). Recommended postdoctoral training in psychopharmacology for prescription privileges: Interim document approved by council. Washington, DC: Author.
13. Apter, A., Ratzone, G. King, R. A., Weizman, A., Iancu, I., Binder, M., Riddle, M. A. (1994). Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 342-348.
14. Armenteros, J. L., Whitaker, A. H., Welikson, M., Stedge, D. J., & Gorman, J. (1997). Risperidone in adolescents with schizophrenia: An open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 694-700.
15. Barkley, R. A., & Cunningham, C. E. (1979). The effects of methylphenidate on the mother-child interactions of hyperactive children. Archives of General Psychiatry, 36, 201-208.
16. Barkley, R. A., Karlson, J., Strezelecki, E., & Murphy, J. V. (1984). Effects of age and Ritalin dosage on the mother-child interactions of hyperactive children. Journal of Consulting and Clinical Psychology, 52, 750-758.
17. Barkley, R. A., McMurray, M. B., Edelbrock, C. S., & Robbins, K. (1990). Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systematic, placebo-controlled evaluation. Pediatrics, 86, 184-192.
18. Barrickman, L., Perry, P. J., Allen, A. J., Kuperman, S., Arndt, S. V., Hermann, K. J., & Schumacher, E. (1995). Bupropion versus methylphenidate in the treatment of attention deficit disorder. Journal of the Academy of Child and Adolescent Psychiatry, 34, 649-657.
19. Bennett, F. C., Brown, R. T., Craver, J., & Anderson, D. (1999). Stimulant medication for the child with attention-deficit hyperactivity disorder. The Pediatric Clinics of North America, 46, 929-944.
20. Birmaher, B. (1998). Should we use antidepressant medication for children and adolescents with depressive disorders? Psychopharmacology Bulletin, 34, 35-39.
21. Boulos, C., Kutcher, S., Marton, P., Simeon, J. Ferguson, B., Roberts, N., & Young, E. (1991). Response to desipramine treatment in adolescent major depression. Psychopharmacology Bulletin, 27, 60-65.
22. Brown, R. T. (2002). Society of Pediatric Psychology presidential address: Toward a social ecology of pediatric psychology. Journal of Pediatric Psychology, 27, 191-201.
23. Brown, R. T., & Donegan, J. E. (1995). The growing impact of neurology. In D. K. Reid, W. P. Hresko, & H. L. Swanson (Eds.), Cognitive approaches to learning disabilities (3rd ed., pp. 153-211). Austin, TX: Pro-Ed.
24. Brown, R. T., & Freeman, W. S. (in press). Primary care. In D. Marsh & M. Fristad (Eds.), Handbook of serious emotional disturbance in children and adolescents. New York: Wiley.
25. Brown, R. T., & Sawyer, M. G. (1998). Medications for school-age children: Effects on learning and behavior. New York: Guilford Press.
26. Buhrmester, D., Whalen, C. K., Henker, B., McDonald, V., & Hinshaw, S. P. (1992). Prosocial behavior in hyperactive boys: Effects of stimulant medication and comparison normal controls. Journal of Abnormal Child Psychology, 20, 103-121.
27. Campbell, M., & Armenteros, J. (1996). Schizophrenia and other psychotic disorders. In J. Weiner (Ed.), Diagnosis of psychopathology of childhood and adolescent disorders (2nd ed., pp. 193-227). New York: Wiley.
28. Campbell, M., Kafantaris, V., & Cueva, J. E. (1995). An update on the use of lithium carbonate in aggressive children and adolescents with conduct disorders. Psychopharmacology Bulletin, 31, 93-102.
29. Campbell, M., Small, A. M., Green, W. H., Jennings, S. J., Perry, R., Bennett, W., & Anderson, L. (1984). Behavioral efficacy of haloperidol and lithium carbonate: A comparison in aggressive children with conduct disorder. Archives of General Psychiatry, 41, 630-636.
30. Connor, D. F., Ozbayrak, K. R., Harrison, R. J., & Melloni, R. H. (1998). Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment. Journal of Child and Adolescent Psychopharmacology, 8, 27-38.
31. Corkum, P., Rimer, P., & Schachar, R. (1999). Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: Impact on enrollment and adherence to a 12-month treatment trial. Canadian Journal of Psychiatry, 44, 1043-1048.
32. Cosgrove, P. V. F. (1994). Fluvoxamine in the treatment of depressive illness in children and adolescents. Journal of Psychopharmacology, 8, 118-123.
33. Dahlquist, L.M. (1999). Pediatric pain management. New York: Kluwer/Plenum.
34. De Leon, P. H., & Wiggins, J. G. (1996). Prescription privileges for psychologists. American Psychologist, 51, 198-206.
35. Delitio, J., Levitan, D., Damore, J., Hajal, F., & Zambenedetti, M. (1997). Naturalistic experience with the use of divalproex sodium on an inpatient unit for adolescent psychiatric patients. Acta Psychiatrica Scandinavia, 97, 236-240.
36. DeVane, C. L., & Sallee, F. R. (1996). Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: A review of published experience. Journal of Clinical Psychiatry, 57, 55-66.
37. DeVeaugh-Geiss, J., Moroz, G., Biederman, J., Cantwell, D., Fontaine, R., Greist, J. A., et al. (1992). Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: A multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 45-49.
38. Drotar, D. (1995). Consulting with pediatricians: Psychological perspectives. New York: Plenum.
39. Dulcan, M. K., Bregman, J., Weller, E. B., & Weller, R. B. (1998). Treatment of childhood and adolescent disorders. In A. F. Schatzberg & C. B. Nemeroff (Eds.), Textbook of psychopharmacology (2nd ed., pp. 803-850). Washington, DC: American Psychiatric Press.
40. DuPaul, G. J., Barkley, R. A., & Conner, D. F. (1998). Stimulants. In R. A. Barkley (Ed.), Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment (pp. 510-551). New York: Guilford Press.
41. DuPaul, G. J., & Kyle, K. E. (1995). Pediatric pharmacology and psychopharmacology. In M. C. Roberts (Ed.), Handbook of pediatric psychology (2nd ed., pp. 741-758). New York: Guilford Press.
42. DuPaul, G. J., & Rapport, M. (1993). Does methylphenidate normalize the classroom performance of children with attention deficit disorder? Journal of the American Academy of Child and Adolescent Psychiatry, 32, 190-198.
43. Emslie, G. J., & Mayes, T.L. (2001). Mood disorders in children and adolescents: Psychopharmacological treatment. Biological Psychiatry, 15, 1082-1090.
44. Emslie, G. J., Mayes, T. L., & Hughes, C. W. (2000). Update in the pharmacological treatment of childhood depression. Psychiatric Clinics of North America, 23, 811-821.
45. Emslie, G. J., Rush, A. J., Weinberg, W. A., & Kowatch, R. A. (1997). A double-blind randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54, 1031-1037.
46. Emslie, G. J., Walkup, J. T., Pliszka, S. R., & Ernst, M. (1999). Nontricyclic antidepressants: Current trends in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 517-528.
47. Ernst, M., Malone, R. P., Rowan, A. B., George, R., Gonzalez, N. M., & Silva, R. R. (1999). Antipsychotics (neuroleptics). In J. S. Werry & M. G. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 297-320). New York: Plenum.
48. Fleischaker, C., Schulz, E., & Remschmidt, H. (1998). Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia. Journal of Psychiatric Research, 32, 325-333.
49. Fox, M. H., Foster, C. H., & Zito, J. M. (2000). Building pharmacoepidemiological capacity to monitor psychotropic drug use among children enrolled in Medicaid. American Journal of Medical Quality, 15, 123-136.
50. Foxman, B., Valdex, R. B., & Brook, R. H. (1986). Childhood enuresis: Prevalence, perceived impact, and prescribed treatments. Pediatrics, 77, 482-487.
51. Gadow, K. D. (1997). An overview of three decades of research in pediatric psychopharmacoepidemiology. Journal of Child and Adolescent Psychopharmacology, 7, 219-236.
52. Gadow, K. D. (1999). Prevalence of drug therapy. In J. S. Werry & M. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 355-385). New York: Plenum.
53. Gadow, K. D., Nolan, E. E., Paolicelli, L. M., & Sprafkin, J. (1991). A procedure for assessing the effects of methylphenidate in hyperactive children in public school settings. Journal of Clinical Child Psychology, 20, 268-276.
54. Geller, B., Cooper, J. B., Sun, K., Zimmerman, B., Frazier, J., Williams, M., & Heath, J. (1998). Double-blind and placebo controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 171-178.
55. Glazener, C. M., & Evans, J. H. (2000). Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Systematic Reviews, 2, pCD002117.
56. Graae, F., Milner, J., Rizzotto, L., & Klein, R. G. (1994). Clonazepam in childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 372-376.
57. Hill, B. K., Balow, E. A., & Bruininks, R. H. (1985). A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacology Bulletin, 21, 279-284.
58. Hinshaw, S. P. (1991). Stimulant medication and the treatment of aggression in children with attention deficits. Journal of Clinical Psychology, 17, 393-407.
59. Hinshaw, S. P. (2000). Family processes and treatment outcomes in the MTA: Negative/ineffective parenting practices in relations to multimodal treatment. Journal of Abnormal Child Psychology, 28, 555-568.
60. Horrigan, J. P., & Barnhill, L. J. (1998). Does guanfacine trigger mania in children? Journal of Child and Adolescent Psychopharmacology, 8, 149-150.
61. Hunt, R. D., Capper, L., & O'Connell, P. (1990). Clonidine in child and adolescent psychiatry. Journal of Child and Adolescent Psychopharmacology, 1, 87-102.
62. Jacobovitz, D., Sroufe, L. A., Stewart, M., & Leffert, N. (1990). Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: A comprehensive review. Journal of the American Academy of Child and Adolescent Psychiatry, 29, 677-688.
63. Jensen, P. S., Bhatara, V. S., Vitiello, B., Hoagwood, K., Feil, M., & Burke, L. B. (1999). Psychoactive medication prescribing practices for U.S. children: Gaps between research and clinical practice. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 557-565.
64. Johnston, C., & Fine, S. (1993). Methods of evaluating methylphenidate in children with attention-deficit hyperactivity disorder: Acceptability, satisfaction, and compliance. Journal of Pediatric Psychology, 18, 717-730.
65. Kaplan, S. L., Simms, R. M., & Busner, J. (1994). Prescribing practices of outpatient child psychiatrists. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 35-44.
66. Kastner, T., Finesmith, R., & Walsh, K. (1993). Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. Journal of Clinical Psychopharmacology, 13, 448-451.
67. Kearney, C., & Silverman, W. (1998). Critical review of pharmacotherapy for youth with anxiety disorders. Journal of Anxiety Disorders, 12, 83-102.
68. Keller, M. B., Lavori, P. W., & Beardslee, W. R., Wunder, J., & Ryan, N. (1991). Depression in children and adolescents: New data on "under treatment" and a literature review on the efficacy of available treatments. Journal of Affective Disorders, 21, 163-171.
69. Klein, R. G., & Mannuzza, S. (1988). Hyperactive boys almost grown up: Part 3. Methylphenidate effects on ultimate height. Archives of General Psychiatry, 45, 1131-1134.
70. Kovacs, M., Feinberg, T. L., Crouse-Novak, M., Paulauskas, S. L., Pollock, M., & Finkelstein, R. (1984). Depressive disorders in childhood: Vol. 2. A longitudinal study of the risk for a subsequent major depression. Archives of General Psychiatry, 41, 643-649.
71. Krener, P. K., & Mancina, R. A. (1994). Informed consent or informed coercion? Decision-making in pediatric psychopharmacology. Journal of Child and Adolescent Psychopharmacology, 4, 183-200.
72. Kumra, S., Frazier, J., Jaconsen, L., McKenna, K., Gordon, C., Lenane, M., et al. (1996). Childhood-onset schizophrenia: A double-blind clozapinehaloperidol comparison. Archives of General Psychiatry, 53, 1090-1097.
73. Kumra, S., Jacobsen, L., Lenane, M., Karp, B., Frazier, J., Smith, A., et al. (1998). Childhood-onset schizophrenia: An open-label study of olanzapine in adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 377-386.
74. Kutcher, S. P. (2000). Practical clinical issues regarding child and adolescent psychopharmacology. Child and Adolescent Psychiatric Clinics of North America, 9, 245-260.
75. Kutcher, S., Boulos, C., Ward, B., Marton, P., Simeon, J., Ferguson, B., et al. (1994). Response to desipramine treatment in adolescent depression: A fixed dose, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1139-1144.
76. Kutcher, S. P., Reiter, S., Gardner, D. M., & Klein, R. G. (1992). The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatric Clinics of North America, 15, 641-686.
77. Kye, C. H., Waterman, G. S., Ryan, N. D., Birmaher, B., Williamson, D. E., Iyengar, S., & Dachille, S. (1996). A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1139-1144.
78. Leonard, H. L., Swedo, S. E., Lenane, M. C., Rettew, D. C., Cheslow, D. L., Hamburger, S. D., & Rapoport, J. L. (1991). A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry, 48, 922-927.
79. Liu, C., Robin, A. L., Brenner, A., & Eastman, J. (1991). Social acceptability of methylphenidate and behavior modification for treating attention deficit hyperactivity disorder. Pediatrics, 88, 560-565.
80. Martin, A., Kaufman, J., & Charney, D. (2000). Pharmacotherapy of early-onset depression: Update and new directions. Child and Adolescent Psychiatric Clinics of North America, 9, 135-157.
81. Mellon, M. W., & McGrath, M. L. (2000). Empirically supported treatments in pediatric psychology: Nocturnal enuresis. Journal of Pediatric Psychology, 25, 193-214.
82. Morris, R. J., & Kratochwill, T. R. (1998). The practice of child therapy (3rd ed.). Boston: Allyn & Bacon.
83. Multimodal Treatment Study for Children With ADHD Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073-1086.
84. Ollendick, T. H., & King, N. J. (1998). Empirically supported treatments for children with phobic and anxiety disorders, Journal of Clinical Child Psychology, 27, 146-155.
85. Onofry, M., Paci, C., D'Andreamatteo, G., & Toma, L. (2000). Olanzapine in severe Gilles de la Tourette syndrome. Journal of Neurology, 247, 443-446.
86. Papatheodorou, G., & Kutcher, S. (1993). Divalproex sodium treatment in late adolescent and young adult acute mania. Psychopharmacology Bulletin, 29, 213-219.
87. Papatheodorou, G., Kutcher, S., Katic, M., & Szalai, J. P. (1995). The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: An open clinical trial. Journal of Clinical Psychopharmacology, 15, 110-116.
88. Parraga, H. C., & Parraga, M. I. (2001). Quetiapine treatment in patients with Tourette's syndrome. Canadian Journal of Psychiatry, 46, 184-185.
89. Paxton, J. W., & Dragunow, M. (1993). Pharmacology. In J. S. Werry & M. G. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (pp. 23-25). New York: Plenum.
90. Pelham, W. E. (1999). The NIMH multimodal treatment study for attention-deficit hyperactivity disorder: Just say yes to drugs alone? Canadian Journal of Psychiatry, 44, 981-990.
91. Pelham, W. E., Gnagy, E. M., Chronic, A. M., Burrows-MacLean, L., Fabiano, G. A., Onyango, A. N., et al. (1999). A comparison of morning only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 104, 1300-1311.
92. Pelham, W. E., Gnagy, E. M., Greiner, A. R., Hoza, B., Hinshaw, S. P., Swanson, J. M., et al. (2000). Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology, 28, 507-525.
93. Perry, R., Petaki, C., Munoz-Silva, D. M., Armenteros, J., & Silva, R. R. (1997). Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. Journal of Child and Adolescent Psychopharmacology, 7, 167-179.
94. Phelps, L., Brown R. T., & Power, T. (2001). Pediatric psychopharmacology: Combining medical and psychosocial intervention. Washington, DC: American Psychological Association.
95. Pleak, R. R., Birmaher, B., Gavrilescu, A., Abichandani, C., & Williams, D. T. (1988). Mania and neuropsychiatric excitation following carbamazepine. Journal of the Academy of Child and Adolescent Psychiatry, 26, 127-132.
96. Poindexter, A. R., Cain, N., Clarke, D. J., Cooke, E. H., Corbett, J. A., Levitas, A. (1998). Mood stabilizers. In S. Reiss & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 215-228). Columbus: Ohio State University, Nisonger Center.
97. Power, T. J., Hess, L. E., & Bennett, D. S. (1995). The acceptability of interventions for attention deficit disorder among elementary and middle school teachers. Developmental and Behavioral Pediatrics, 16, 238-243.
98. Prochaska, J. O., DiClemente, C. C., & Norcross, J. C. (1992). In search of how people change: Applications to addictive behaviors. American Psychologist, 47, 1101-1114.
99. Purdon, S. E., Lit, W., Labelle, A., & Jones, B. D. (1994). Risperidone in the treatment of pervasive developmental disorder. Canadian Journal of Psychiatry, 39, 400-405.
100. Rappley, M. D., Mullan, P. B., Alvarezz, F. J., Eneli, I. U., Wang, J., & Gardiner, J. C. (1999). Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children. Archives of Pediatric and Adolescent Medicine, 153, 1039-1045.
101. Rey-Sanchez, F., & Gutierrez-Casares, J. (1997). Paroxetine in children with major depressive disorder: An open trial. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 1143-1147.
102. Riddle, M. A., Geller, B., & Ryan, N. (1993). Another sudden death in a child treated with desipramine. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 792-797.
103. Rifkin, A., Karajgi, B., Dicker, R., Perl, E., Boppana, V., Hasan, N., & Pollack, S. (1997). Lithium treatment of conduct disorders in adolescents. American Journal of Psychiatry, 154, 554-555.
104. Robertson, M. M., & Stern, J. S. (2000). Gilles de la Tourette syndrome: Symptomatic treatment based on evidence. European Child and Adolescent Psychiatry, 9(Suppl. 1), 160-175.
105. Safer, D. J., & Krager, J. M. (1988). A survey of medication treatment for hyperactive/inattentive students. Journal of the American Medical Association, 260, 2256-2258.
106. Safer, D. J., Zito, J. M., & Fine, E. M. (1996). Increased methylphenidate usage for attention deficit disorder in the 1990's. Pediatrics, 98, 1084-1088.
107. Sallee, F. R., Goetz, C. G., Singer, J., Scahill, L., Law, G., Dittman, V. M., & Chappell, P. B. (2000). Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 292-299.
108. Sallee, F. R., Hilial, R., Dougherty, D., Beach, K., & Nesbitt, L. (1998). Platelet serotonin transporter in depressed children and adolescents: 33H-paroxetine platelet binding before and after sertaline. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 777-784.
109. Shelton, T., & Barkley, R. A. (1995). The assessment and treatment of attention deficit hyperactivity disorder in children. In M. Roberts (Ed.), Handbook of pediatric psychology (2nd ed., pp. 663-754). New York: Guilford Press.
110. Shelton, R. C., Keller, M. B., Gelenberg, A., Dunner, D. L., Hirschfield, R., Thase, M. E., et al. (2001). Effectiveness of St. John's wort in major depression: A randomized controlled trial. Journal of the American Medical Association, 285, 1978-1986.
111. Shouten, R., & Duckworth, K. S. (1999). Medicolegal and ethical issues in the pharmacologic treatment of children. In J. Werry & M. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 99-164). New York: Plenum.
112. Silver, A. A., Shytle, R. D., Sheehan, K. H., Sheehan, D. V., Ramos, A., & Sanberg, P. R. (2001). Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1103-1110.
113. Stahl, S. M. (1999). Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. Journal of Clinical Psychiatry, 60(Suppl. 10), 31-41.
114. Stancin, T. (1999). Pediatric mental health services in primary care settings [Introduction to special issue]. Journal of Pediatric Psychology, 24, 367-368.
115. Stefl, M. E., Bornstein, R. A., & Hammond, L. (1987). The 1987 Ohio Tourette Survey. Milford: Tourette Syndrome Association of Ohio.
116. Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., et al. (1999). Acute tolerance to methylphenidate in the treatment of ADHD in children. Clinical Pharmacological Therapy, 66, 295-305.
117. Tarnowski, K. J., & Brown, R. T. (1995). Pediatric burns. In M. C. Roberts (Ed.), Handbook of pediatric psychology (2nd ed., pp. 446-462). New York: Guilford Press.
118. Tarnowski, K. J., Brown, R. T., Dingle, A. D., & Dreelin, E. (1998). Pediatric pain. In R. T. Ammerman & J. V. Campo (Eds.), Handbook of pediatric psychology and psychiatry (Vol. 2, pp. 453-476). Mahwah, N.J.: Erlbaum.
119. Turetz, M., Mozes, T., Toren, P., Chernauzan, N., Yoran-Hegesh, R., Mester, R., et al. (1997). An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. British Journal of Psychiatry, 170, 507-510.
120. Varley, C., & McClellend, J. (1997). Two additional sudden deaths with tricyclic antidepressants. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 390-395.
121. Vining, E., Carpenter, R. O., & Aman, M. G. (1999). Antiepileptics (anticonvulsants). In J. Werry & M. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 355-385). New York: Plenum.
122. Vitiello, B. (2001). Psychopharmacology for young children: Clinical needs and research opportunities. Pediatrics, 108, 983-989.
123. Walter, G., & Rey, R. M. (1999). Use of St. John's Wort by adolescents with a psychiatric disorder. Journal of Child and Adolescent Psychopharmacology, 9, 307-311.
124. Weisz, J. R., & Jensen, P. S. (1999). Efficacy and effectiveness of child and adolescent psychotherapy and pharmacotherapy. Mental Health Services Research, 1, 125-157.
125. Werry, J. S. (1995). Resolved: Cardiac arrhythmias make desipramine an unacceptable choice in children. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1239-1245.
126. Werry, J. S., & Aman, M. G. (1999). Anxiolytics, sedatives, and miscellaneous drugs. In J. Werry & M. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 433-469). New York: Plenum.
127. West, S., Keck, P., & McElroy, S. (1995). Oral loading doses in the valproate treatment of adolescents with mixed bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 5, 225-231.
128. Whalen, C. K., Henker, B., Hinshaw, S. P., & Granger, D.A. (1989). Externalizing behavior disorders, situational generality, and Type A behavior pattern. Child Development, 60, 1453-1462.
129. Wilens, T., Spencer, T., Biederman, J., & Schleifer, D. (1997). Case study: Nefazodone for juvenile mood disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 481-485.
130. Young, J. M., Shytle, R. D., Sanberg, P. R., & George, T. P. (2001). Mecamylamine: New therapeutic uses and toxicity/risk profile. Clinical Therapeutics, 23, 532-565.
131. Zametkin, A. J., & Yamada, E. M. (1999). Monitoring and measuring drug effects: Vol. 1. Physical effects. In J. Werry & M. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed., pp. 69-97). New York: Plenum.
132. Zeiner, P. (1995). Body growth and cardiovascular function after extended treatment (1.75 years) with methylphenidate in boys with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 5, 129-138.
133. Zito, J. M., Safer, D. J., dosReis, S., Gardner, J. F., Boles, M., & Lynch, F. (2000). Trends in the prescribing of psychotropic medications to preschoolers. Journal of the American Medical Association, 283, 1025-1030.
134. Zito, J. M., Safer, D. J., dos Reis, S., & Riddle, M. A. (1998). Racial disparity in psychotropic medications prescribed for youths with Medicaid insurance in Maryland. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 179-184.
135. Zuddas, A., Pintor, M., & Cianchetti, C. (1996). Risperidone for negative symptoms [Letter]. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 838-839.